Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients

Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, M, Tomita, Y, Imai, T, Saito, T, Katagiri, A, Tanikawa, T, Takeda, M, Takahashi, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363168/
https://www.ncbi.nlm.nih.gov/pubmed/10408413
http://dx.doi.org/10.1038/sj.bjc.6690576
Descripción
Sumario:Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevated sCD95 group. Serum sCD95 level was shown to be an independent prognostic factor by univariate and multivariate analysis, indicating a possible significant role in determining treatment strategies. © 1999 Cancer Research Campaign

Ejemplares similares